Thursday April 25, 2024 8am PT, 11am ET
Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets
To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development. In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success.
Speaker: Ross Chambers, PhD, VP of Antibody Discovery, Integral Molecular
Registration is open!
Thursday June 6, 2024 8am PT, 11am ET
Advancing early-stage bispecific discovery programs towards clinical success, with GS Discovery® and bYlok® technology
In this webinar Dr. Jin Lu will show how Lonza’s novel GS Discovery® transient expression platform can boost transient titers by ~30-fold to enable rapid early material supply, and streamline the transition from discovery to stable production. Dr. Lu will also introduce bYlok® bispecific pairing technology – an innovative solution that drives correct heavy-light chain pairing rates in IgG-like bispecifics to >95%. This improves yields of the correct species and streamlines downstream processing, without affecting key performance attributes of the molecule. Dr. Lu will present the latest case studies of bYlok® engineered bispecifics and explore how bYlok® compares to other established pairing solutions.
Key points:
- GS Discovery® supports high titer transient expression to rapidly generate material for early studies
- bYlok® bispecific pairing technology drives correct HC-LC pairing in bispecifics to >95%
- This overcomes issues during downstream processing
- bYlok® and GS Discovery® are accessible via a license agreement
Speaker: Dr. Jin Lu, PhD, Senior Technical Support Manager, Licensing, Lonza
Dr. Jin Lu is a senior technical support manager for technology licensing at Lonza. She has over 13 years of experience in biotherapeutic protein characterization, and a PhD in chemical biology from The University of Warwick, UK.
Registration is open!
Note: The webinar platform and registration process is managed by Community Brands.
Their privacy policy is here.
Our selection of On Demand webinars can be viewed here.
Our YouTube channel includes selected webinars as well as recordings of our Symposia on topics such as:
- Computational Antibody Discovery: State of the Art
- Biopharmaceutical Informatics
- Harnessing Cytokines for Cancer Immunotherapy
- Emerging Immunotherapeutics for Ovarian Cancer Symposium
- Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells